Appendix on transparency rules to the Functional ...
Appendix, on disclosure rules, to the “Functional specifications for the EU portal and EU database to be audited - EMA/42176/2014” EMA/228383/2015 Page 2/29
Download Appendix on transparency rules to the Functional ...
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Product, Management, Lifecycle, Product lifecycle management
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guidelines, Good, Practices, Clinical, Good clinical practice e6
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients
Related documents
Fundamentals of Care - NHS Wales
www.wales.nhs.ukpatients have the right to a clear explanation of all proposed treatments, including any risks involved and the alternatives before giving consent. The provision of information is one of the driving forces of NHS philosophy, and communication with users of health and social care services is a key principle of a recent Welsh Assembly
Assessment and Case Formulation in Counselling and ...
www.ecronicon.com12 months’ post-treatment ‘generic counselling’ was as viable as ‘medication treatment’, and patients favoured counselling. The absence of specificity about the kind of counselling gave was a shortcoming in this review. Recommended by NICE guidelines, CBT therapy as opposed to medications for mild depression.
Nursing and Midwifery Council Fitness to Practise Committee
www.nmc.org.ukDec 13, 2021 · Part(s) of the register: Registered Nurse – Sub Part 1 Mental Health Nursing – September 1998 Area of ... Outcome: Suspension order for 6 months to come into effect on 23 January 2022 in accordance with ... date and the GoToMeeting link of the virtual hearing and, amongst other things, information about Mr Mahandru’s right to attend, be ...
LAYOUT HPV Layout 1 27/5/2019 12:20 PM Page a - OGSM
www.ogsm.org.mywomen and ranks the 7th amongst Malaysians. The incidence of cervical cancer has increased from 6.5 per 100000 population in 2011 year to 10.5 per 100000 population in 2018. The National Cancer Blue-Print 2016-2020 highlights the ministry’s commitment towards control and prevention of cancer. Strategies to
The awareness of emotional intelligence by nurses and ...
shura.shu.ac.ukThis outcome supports the findings of research by Akerjordet and Severinsson [15] who found that emotional intelligence is central to ... study into emotional intelligence and stress amongst students from four health professions; dentistry, nursing, medicine and mental health, over a period of one year. ... Ward staff included both Registered ...
Intelligence, Outcome, Nurse, Emotional, Registered, Awareness, Amongst, The awareness of emotional intelligence by nurses and
Use of Symbols to Indicate Compliance with the MDR ...
www.medtecheurope.orgGUIDANCE www.medtecheurope.org Page 1 of 16 Use of Symbols to Indicate Compliance with the MDR December 2019 Version 2.0 (replaces original version of May 2019) The Medical Devices Regulation 2017/745/EU (‘MDR’) has new requirements that ask for various kinds of information to be indicated on the label of medical devices.
Nursing and Midwifery Council Fitness to Practise Committee
www.nmc.org.ukNov 04, 2021 · registered address by recorded delivery and by first class post on 30 September 2021. The panel took into account that the Notice of Hearing provided details of the allegation, the time, dates and venue of the hearing and, amongst other things, information about